Healthcare / BiotechnologyKOSDAQ
$3105.00
-100.00 (-3.21%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 20%
FCF escenarios
weak_data · normalized FCF $-20.6B · quality 56.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
10/100
F
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$39.7B
P/E
N/A
•EV/EBITDA
12.3x
↑ROE
-11.1%
↓Gross Margin
5.5%
↓Debt/Equity
1.44
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.8%
FCF CAGR
—
FCF margin
-29.7%
FCF / Net income
5.10x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $47.75B · net income $-2.78B · FCF $-14.18B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $47.75B | $47.75B | $35.97B | $26.59B | $44.01B |
| Net Income | $-2.78B | $-2.78B | $-2.00B | $-16.64B | $5.26B |
| EBITDA | $6.13B | $6.13B | $4.94B | $-12.05B | $8.62B |
| EPS | -393.00 | -393.00 | -424.00 | -1311.00 | 258.50 |
| Gross Margin | 5.5% | 5.5% | -8.6% | -25.3% | 20.4% |
| Operating Margin | -12.0% | -12.0% | -19.9% | -45.6% | 12.0% |
| Net Margin | -5.8% | -5.8% | -5.6% | -62.6% | 11.9% |
| Balance Sheet | |||||
| Debt/Equity | 1.44 | 1.44 | 0.97 | 0.50 | 0.11 |
| Current Ratio | 0.66 | 0.66 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-14.18B | $-14.18B | $-25.69B | $-20.57B | $-9.86B |
| Returns | |||||
| ROE | -11.1% | -11.1% | -7.0% | -52.5% | 11.3% |
| Valuation | |||||
| P/E | — | — | — | — | 18.20 |
| EV/EBITDA | 12.31 | 12.31 | 10.31 | — | 3.74 |
| P/B | 1.58 | 1.58 | 0.97 | 7.14 | 1.03 |
| Growth & Yield | |||||
| Revenue Growth | 32.7% | 32.7% | 35.3% | -39.6% | — |
| EPS Growth | 7.3% | 7.3% | 67.7% | -607.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-30.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-424.00 → -393.00
Residual
-30.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.